Hydrazines

Monoamine Oxidase Inhibitors Pipeline Insight Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Monday, July 5, 2021
Health, Pharmaceutical, Psychoactive drugs, Monoamine oxidase inhibitors, Drugs, Amphetamine, Antidepressants, Hydrazines, Reversible inhibitors of MAO-A, Monoamine neurotransmitter, Monoamine oxidase, Tetrindole, Luteusin A

The "Monoamine Oxidase Inhibitors - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Monoamine Oxidase Inhibitors - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This "Monoamine Oxidase Inhibitors - Pipeline Insight, 2021" report provides comprehensive insights about 7+ companies and 7+ pipeline drugs in Monoamine Oxidase Inhibitors pipeline landscape.
  • This segment of the report provides insights about the different Monoamine Oxidase Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
    There are approx.
  • Monoamine Oxidase Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

2021 Global Hydrazine Dihydrochloride (CAS 5341-61-7) Market Research Report - Downstream Industry Trends - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 23, 2021
Chemicals, Plastics, Other Manufacturing, Manufacturing, Monoamine oxidase inhibitors, Hydrazines, Hepatotoxins, Chemical substances, Chemistry, Physical sciences, Occupational safety and health, Rocket fuels, Hydrazine, Phenoxypropazine

The "Hydrazine dihydrochloride (CAS 5341-61-7) Global Market Research Report 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Hydrazine dihydrochloride (CAS 5341-61-7) Global Market Research Report 2021" report has been added to ResearchAndMarkets.com's offering.
  • This global report is a result of industry experts' diligent work on researching the world market of Hydrazine dihydrochloride.
  • The Hydrazine dihydrochloride global market report key points:
    The first chapter introduces the product (composition, structure, hazards, storage, toxicological & ecological information, etc.).
  • The fifth chapter deals with Hydrazine dihydrochloride market trends and forecast, distinguish Hydrazine dihydrochloride manufacturers and suppliers.

Global Hydrazine Tartrate (CAS 634-62-8) Market Research Report 2021 - Downstream Industry Trends - ResearchAndMarkets.com

Retrieved on: 
Monday, June 21, 2021
Chemicals, Plastics, Manufacturing, Enzymes, Monoamine oxidase inhibitors, Hydrazines, Hydrazine, Occupational safety and health, L(+)-tartrate dehydratase, D(-)-tartrate dehydratase, Azine, Tartrate

The "Hydrazine tartrate (CAS 634-62-8) Global Market Research Report 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Hydrazine tartrate (CAS 634-62-8) Global Market Research Report 2021" report has been added to ResearchAndMarkets.com's offering.
  • This global report is a result of industry experts' diligent work on researching the world market of Hydrazine tartrate.
  • The Hydrazine tartrate global market report key points:
    The first chapter introduces the product (composition, structure, hazards, storage, toxicological & ecological information, etc.).
  • The fifth chapter deals with Hydrazine tartrate market trends and forecast, distinguish Hydrazine tartrate manufacturers and suppliers.

Strong Sobi presence at American Society of Hematology 2020 Annual Meeting

Retrieved on: 
Friday, November 6, 2020
Health sciences, Health, Orphan drugs, Thrombopoietin receptor agonists, Breakthrough therapy, Eltrombopag, Hydrazines, Immune thrombocytopenic purpura, Swedish Orphan Biovitrum, Pharmacokinetics, Thrombocytopenia, ITP

STOCKHOLM, Nov. 6, 2020 /PRNewswire/ -- Sobi will present data at the 62nd Annual Meeting of the American Society of Hematology (ASH) taking place taking place as a virtual meetingfrom 5-8 December.

Key Points: 
  • STOCKHOLM, Nov. 6, 2020 /PRNewswire/ -- Sobi will present data at the 62nd Annual Meeting of the American Society of Hematology (ASH) taking place taking place as a virtual meetingfrom 5-8 December.
  • #848 Pharmacokinetic/Phamacodynamic (PK/PD) Modeling Providing Guidance for Selecting Avatrombopag (AVA) Dose When Switching from Eltrombopag in Chronic Immune Thrombocytopenia (ITP).
  • Sobi has final development and commercialisation rights in the Sobi territory (essentially Europe, North Africa, Russia and most Middle Eastern markets).
  • Sobi is providing sustainable access to innovative therapies in the areas of haematology, immunology and specialty indications.

Neurocrine Biosciences Announces Once-Daily ONGENTYS® (opicapone) Now Available in the U.S. as an Add-On Treatment for Patients with Parkinson's Disease Experiencing "Off" Episodes

Retrieved on: 
Monday, September 14, 2020
Drugs, Catecholamines, RTT, Combination drugs, Carbidopa, Hydrazines, Prodrugs, Parkinson's disease, L-DOPA, Carbidopa/levodopa/entacapone, Catechol-O-methyltransferase inhibitor

ONGENTYS was approved by the U.S. Food and Drug Administration (FDA) on April 24, 2020, as an add-on treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing "off" episodes.

Key Points: 
  • ONGENTYS was approved by the U.S. Food and Drug Administration (FDA) on April 24, 2020, as an add-on treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing "off" episodes.
  • ONGENTYS helps protect levodopa by reducing its breakdown in the bloodstream, making more levodopa available to reach the brain.
  • "The availability of ONGENTYS offers hope to patients by significantly reducing daily 'off' time, when symptoms return between regular doses of levodopa/carbidopa.
  • The availability of ONGENTYS underscores our commitment to delivering innovative therapies that address unmet medical needs in patients living with movement disorders."

Neurocrine Biosciences Presents New Data Analyses Demonstrating Efficacy of FDA-Approved Once-Daily ONGENTYS® (opicapone) in Patients with Parkinson's Disease at the MDS Virtual Congress 2020

Retrieved on: 
Friday, September 11, 2020
Drugs, Health, Catecholamines, RTT, Combination drugs, Amino acids, Carbidopa, Hydrazines, Parkinson's disease, L-DOPA, Carbidopa/levodopa/entacapone, Management of Parkinson's disease

These data are among several studies and analyses of ONGENTYS being presented in collaboration with BIAL at the MDS Virtual Congress 2020 on September 1216 ( www.mdscongress.org/Congress/Registration.htm ).

Key Points: 
  • These data are among several studies and analyses of ONGENTYS being presented in collaboration with BIAL at the MDS Virtual Congress 2020 on September 1216 ( www.mdscongress.org/Congress/Registration.htm ).
  • "The Phase III post-hoc data analyses demonstrated the benefit of adding once-daily ONGENTYS to levodopa/carbidopa in patients with Parkinson's disease who have motor fluctuations.
  • "These data analyses demonstrated the benefit of adding once-daily ONGENTYS to levodopa/carbidopa earlier in the treatment regimen of patients with Parkinson's disease.
  • Similarly, hospitalizations were significantly more frequent in patients with a longer history of motor fluctuations (15% [n=18] vs 6% [n=12], P

Kyowa Kirin Announces NOURIANZ™ (Istradefylline) Now Available in the U.S. for Treatment of Parkinson’s Disease “Off” Episodes

Retrieved on: 
Monday, October 14, 2019
Biotechnology, Pharmaceutical, Health, Drugs, Catecholamines, Organic compounds, Chemistry, Carbidopa, Hydrazines, Istradefylline, Parkinson's disease, L-DOPA, Kirin, Kyowa Kirin, NOURIANZ™ (istradefylline) tablets, Parkinson's disease

Kyowa Kirin, Inc. (Kyowa Kirin), an affiliate of Kyowa Kirin Co., Ltd. (TSE: 4151), announced today that NOURIANZ (istradefylline) is now available in the U.S. as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinsons disease (PD) experiencing off episodes.

Key Points: 
  • Kyowa Kirin, Inc. (Kyowa Kirin), an affiliate of Kyowa Kirin Co., Ltd. (TSE: 4151), announced today that NOURIANZ (istradefylline) is now available in the U.S. as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinsons disease (PD) experiencing off episodes.
  • To help patients with questions about access to NOURIANZ, Kyowa Kirin offers the Kyowa Kirin Cares program.
  • NOURIANZ (istradefylline) is an adenosine receptor antagonist indicated as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinsons disease (PD) experiencing off episodes.
  • Parkinsons disease is a progressive, neurodegenerative disease characterized by motor symptoms such as tremors, rigidity, slow movement and postural instability.

Kyowa Kirin Announces FDA Approval of NOURIANZ™ (istradefylline) for Use in Parkinson’s Disease

Retrieved on: 
Wednesday, August 28, 2019
FDA, Pharmaceutical, Managed care, General Health, Clinical trials, Science, Biotechnology, Other Science, Nursing, Research, Health, Drugs, Catecholamines, Organic compounds, Chemistry, Carbidopa, Hydrazines, Parkinson's disease, Istradefylline, L-DOPA, Parkinson, Kyowa Kirin, NOURIANZ™ (istradefylline) tablet, Parkinson's disease

Kyowa Kirin Co., Ltd., (Kyowa Kirin, TYO: 4151) announces today that the U.S. Food and Drug Administration (FDA) has granted approval for NOURIANZ (istradefylline) for use as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinsons disease (PD) experiencing OFF episodes.

Key Points: 
  • Kyowa Kirin Co., Ltd., (Kyowa Kirin, TYO: 4151) announces today that the U.S. Food and Drug Administration (FDA) has granted approval for NOURIANZ (istradefylline) for use as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinsons disease (PD) experiencing OFF episodes.
  • We are proud that NOURIANZ is now ready to help adult patients with Parkinsons disease in the US, said Tomohiro Sudo, Head of Global Product Management Office of Kyowa Kirin.
  • We are grateful for the FDA approval and for the many dedicated scientists and patients whose participation in our research programs has resulted in a new treatment option for Parkinson's disease.
  • Parkinsons disease is a progressive, neurodegenerative disease characterized by motor symptoms such as tremors, rigidity, slow movement and postural instability.

Intec Pharma Reports Last Patient Last Visit in Pivotal Phase 3 Trial of Accordion Pill™ Carbidopa/Levodopa for the Treatment of Advanced Parkinson's Disease Patients

Retrieved on: 
Tuesday, April 30, 2019
Drugs, Catecholamines, RTT, Combination drugs, Carbidopa, Hydrazines, L-DOPA

"We are excited to announce that the last patient's last visit has taken place as it is an important milestone in the development of our Accordion Pill platform.

Key Points: 
  • "We are excited to announce that the last patient's last visit has taken place as it is an important milestone in the development of our Accordion Pill platform.
  • Completion of the ACCORDANCE study brings us closer to potentially providing an enhanced baseline levodopa treatment to advanced PD patients," stated R. Michael Gendreau, M.D., Ph.D., Chief Medical Officer of Intec Pharma.
  • The Phase 3 ACCORDANCE clinical trial of AP-CD/LD is a multi-center, global, randomized, double-blind, double-dummy, active-controlled, parallel-group study in adult subjects with advanced PD.
  • The Accordion Pill Carbidopa/Levodopa (AP-CD/LD) is a gastric-retentive drug delivery system containing carbidopa and levodopa in both immediate and extended-release modes.

Global Hydralazine (CAS 86-54-4) Market Research Report 2019 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 27, 2019
Health, Cardiology, Pharmaceutical, Antihypertensive agents, Phthalazines, Hydrazines, Hepatotoxins, Hydralazine, RTT, Medicine, Clinical medicine

The "Hydralazine (CAS 86-54-4) Market Research Report 2019" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Hydralazine (CAS 86-54-4) Market Research Report 2019" report has been added to ResearchAndMarkets.com's offering.
  • This report is a result of industry experts' diligent work on researching the world market of Hydralazine.
  • The Hydralazine global market report 2019 key points:
    The first chapter introduces the product by providing review of the most of its characteristics (composition, structure, hazards, storage, toxicological & ecological information, etc.).
  • The forth chapter deals with Hydralazine market trends review, distinguish Hydralazine manufacturers and suppliers.